SCA
EW icon

Spearhead Capital Advisors’s Edwards Lifesciences EW Stock Holding History

Spearhead Capital Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,838
Closed -$227K – 177
2020
Q3 		$227K Buy
+2,838
New +$221K 0.04% 169

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Spearhead Capital Advisors's EW Position: Q4 2020 in Review

Spearhead Capital Advisors sold out of Edwards Lifesciences (EW) in Q4 2020, closing a stake of 2,838 shares — an estimated $227K sold.

Spearhead Capital Advisors first reported a position in EW in Q3 2020 and held it in 1 quarter. The position peaked at $227K in Q3 2020. 1,158 funds tracked by Wall St. Rank hold EW as of Q4 2020.

  • Spearhead Capital Advisors reported no remaining Edwards Lifesciences position as of Q4 2020 after selling out during the quarter.
  • Spearhead Capital Advisors sold 2,838 Edwards Lifesciences shares in Q4 2020, an estimated $227K.
  • Spearhead Capital Advisors first reported a position in Edwards Lifesciences in Q3 2020 and held it in 1 quarter.
  • Spearhead Capital Advisors's Edwards Lifesciences position peaked at $227K in Q3 2020.
  • 1,158 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2020.

Based on Spearhead Capital Advisors's 13F filing for Q4 2020, filed 2 Feb 2021.